UiPath, Inc. focuses on enterprise automation and AI software, with its roots in robotic process automation. The platform blends reliable automation with AI-driven agentic features, allowing companies to streamline processes in areas like finance, customer service, healthcare, and supply chains. Its offerings include core automation tools, the UiPath Platform, and newer AI solutions designed for more intricate, AI-heavy workflows.
Led by CEO Daniel Dines, PATH operates in a rapidly evolving space where established players such as Microsoft, Salesforce, and ServiceNow are integrating their own AI agents into established products. I follow PATH because of its position in the AI-automation narrative, its subscription revenue base, and ongoing questions about how much an independent orchestration layer can deliver as AI spreads more widely. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In the last 30 days, PATH dropped approximately 34%, moving from a close of $18.67 on August 31 to $12.32 on September 29. Most of the decline hit early in September, with a roughly 16.6% single-day drop right after earnings, and it continued through late September following the investor day that did not introduce new financial targets.
Looking back three months to June 30, when the stock closed at $10.87, PATH is still ahead by about 13% for the quarter overall. The period featured a strong July–August advance fueled by AI-related enthusiasm and a solid fiscal Q1 report, but September’s reversal wiped out most of those earlier gains. From what I see, this contrast highlights how quickly sentiment can shift in the sector.
The main trigger was UiPath’s fiscal Q2 2027 earnings, released after the close on September 3. Revenue came in at $410.3 million, a 13.4% year-over-year increase that beat estimates around $398 million, while non-GAAP EPS of $0.15 matched expectations. Annual recurring revenue grew about 12% to $1.94 billion.
Guidance drew the most attention, however. The third-quarter revenue range of $440 million to $445 million pointed to growth slowing to roughly 8% year over year. Billings also missed slightly, and management noted longer sales cycles as customers evaluate deterministic versus AI-driven automation. The stock fell about 16.6% the next day. I’m watching this closely because further analyst actions added pressure, with Canaccord Genuity moving to Hold and several others, including UBS, Barclays, RBC, Truist, and BMO, lowering targets. After the September 22 investor day, which emphasized AI orchestration without new fiscal 2028 numbers, additional cuts and a downgrade to Underperform from DA Davidson weighed on the shares. Competition and pricing concerns on the AI side played a role as well.
The quarter reflected two distinct phases. July and August brought a sharp rally, with the stock roughly doubling from late-June levels to near $18.67 by late August, as investors moved into AI-linked software names and reacted positively to fiscal Q1 results and improving profitability. Management’s comments on AI demand supported the move.
September reversed that momentum. Even with the revenue beat in Q2, the slower growth outlook and more cautious analyst commentary shifted the tone. Questions about sustaining expansion amid native AI integrations by larger vendors and customer resistance to pricing became more prominent. The result was a quarter that ended modestly higher but far from August peaks.
Attention will center on whether UiPath can regain momentum in ARR and show that its AI orchestration approach supports lasting revenue growth. The December earnings report will serve as an important checkpoint, especially with the CFO transition to Hitesh Ramani now in place.
Competitive dynamics, adoption of newer AI products, and the company’s ability to maintain pricing will remain central. Broader economic conditions, including interest rates and enterprise spending patterns, will also influence valuation given the stock’s sensitivity to growth expectations. These elements together are likely to shape the path ahead.
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum indicators across similar names. The platform’s AI Trend Prediction Engine has also helped me evaluate longer-term patterns without relying solely on traditional metrics. These resources provide an additional layer of data when assessing how PATH fits into the wider automation and AI sector.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
PATH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 37 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 84%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PATH as a result. In 65 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PATH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where PATH advanced for three days, in 236 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PATH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 135 of 173 cases where PATH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.477) is normal, around the industry mean (16.188). P/E Ratio (19.403) is within average values for comparable stocks, (45.064). Projected Growth (PEG Ratio) (0.447) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.427) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (103.301).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PATH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PATH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ComputerCommunications